SM-GNN prunes multi-view GNNs to pure propagation, cutting training time while outperforming prior MKGC accuracies on two ...
Sanofi should hear from the FDA in September about its application for Sarclisa as a first-line therapy for multiple myeloma after the US regulator gave it a priority review. The French pharma group ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results